The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 17, 2024
Filed:
Nov. 23, 2020
Applicant:
Aobiome Llc, Cambridge, MA (US);
Inventors:
David R. Whitlock, Cambridge, MA (US);
Spiros Jamas, Cambridge, MA (US);
Larry Weiss, San Francisco, CA (US);
Ioannis Gryllos, Brookline, MA (US);
Assignee:
AOBIOME LLC, Cambridge, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 1/20 (2006.01); A61K 8/99 (2017.01); A61K 9/00 (2006.01); A61K 35/74 (2015.01); A61K 35/744 (2015.01); A61K 35/745 (2015.01); A61K 35/747 (2015.01); A61K 48/00 (2006.01); A61L 15/36 (2006.01); A61Q 15/00 (2006.01); A61Q 17/04 (2006.01); A61Q 19/00 (2006.01); C07K 14/195 (2006.01); C12N 1/00 (2006.01); C12Q 1/02 (2006.01); C12Q 1/689 (2018.01); A61Q 19/02 (2006.01); A61Q 19/04 (2006.01); C12R 1/01 (2006.01);
U.S. Cl.
CPC ...
C12N 1/20 (2013.01); A61K 8/99 (2013.01); A61K 9/0014 (2013.01); A61K 35/74 (2013.01); A61K 35/744 (2013.01); A61K 35/745 (2013.01); A61K 35/747 (2013.01); A61K 48/00 (2013.01); A61L 15/36 (2013.01); A61Q 15/00 (2013.01); A61Q 17/04 (2013.01); A61Q 19/00 (2013.01); C07K 14/195 (2013.01); C12N 1/00 (2013.01); C12N 1/205 (2021.05); C12Q 1/02 (2013.01); C12Q 1/689 (2013.01); A61Q 19/02 (2013.01); A61Q 19/04 (2013.01); C12R 2001/01 (2021.05);
Abstract
This disclosure provides, inter alia, an optimized strain of() designated D23, D23-100, or AOB D23-100.bacteria disclosed in this application have desirable properties, e.g., optimized properties, such as the ability to suppress growth of pathogenic bacteria, and an enhanced ability to produce nitric oxide and nitric oxide precursors. Theherein may be used, for instance, to treat diseases associated with low nitrite levels, skin diseases, and diseases caused by pathogenic bacteria.